Connect with us

Fibromyalgia

Fibromyalgia patients swap prescription drugs for CBD

Fibromyalgia patients are frequently substituting prescription medications for CBD products

Published

on

Patients frequently acknowledge substituting CBD products for commonly prescribed drugs such as opioids

Fibromyalgia patients are frequently substituting prescription medications for CBD products, according to a new study.

Findings published in the Journal of Pain, report that patients frequently acknowledge substituting CBD products for opioids, NSAIDS and other commonly prescribed medications.

Researchers with the University of Michigan Medical School surveyed 878 fibromyalgia patients who were currently using CBD.

Seventy-two percent of respondents reported deliberately substituting CBD products in place of other medications, specifically opioids, NSAIDS, benzodiazepines, and gabapentanoids.

More than half (53 percent) swapped CBD for opioids and 23 percent used it in place of benzodiazepines.

Among those who used CBD, the majority reported decreasing or stopping use of these pain medications all together.

The most common reasons for substitution were fewer side effects and better symptom management.

The authors noted: “Those who substituted reported larger improvements in health and pain than those who did not. Participants using CBD-cannabis reported significantly more substitutions than any other group and larger improvements in health, pain, memory, and sleep than other subgroups.”

Several other studies indicate that cannabinoids can provide relief to patients with fibromyalgia. 

Data published in February reported that the long-term use of medical cannabis is linked to improvements in pain and other symptoms.

Another study, published in 2020, also reported that cannabis therapy was associated with reductions in the use of prescribed medicines, as well as improvements in sleep and pain.

 

 

Sarah Sinclair is an award-winning freelance journalist covering health, drug policy and social affairs. She is one of the few UK reporters specialising in medical cannabis policy and as the former editor of Cannabis Health has covered developments in the European cannabis sector extensively, with a focus on patients and consumers. She continues to report on cannabis-related health and policy for Forbes, Cannabis Health and Business of Cannabis and has written for The i Paper, Byline Times, The Lead, Positive News, Leafie & others. Sarah has an NCTJ accreditation and an MA in Journalism from the University of Sunderland and has completed additional specialist training through the Medical Cannabis Clinicians Society in the UK. She has spoken at leading industry events such as Cannabis Europa.

Trending

Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2024 PP Intelligence Ltd.